These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 25981922

  • 1. Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.
    Han SY, Zhao W, Sun H, Zhou N, Zhou F, An G, Li PP.
    Phytomedicine; 2015 May 15; 22(5):560-7. PubMed ID: 25981922
    [Abstract] [Full Text] [Related]

  • 2. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
    Han SY, Zhao MB, Zhuang GB, Li PP.
    Lung Cancer; 2012 Jan 15; 75(1):30-7. PubMed ID: 21757251
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY, Zhao HY, Zhou N, Zhou F, Li PP.
    J Ethnopharmacol; 2014 Jan 15; 151(1):210-7. PubMed ID: 24157377
    [Abstract] [Full Text] [Related]

  • 5. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.
    Zhao C, Hao H, Zhao H, Ren W, Jiao Y, An G, Sun H, Han S, Li P.
    J Ethnopharmacol; 2020 Jun 12; 255():112770. PubMed ID: 32205262
    [Abstract] [Full Text] [Related]

  • 6. Nitric oxide, a communicator between tumor cells and endothelial cells, mediates the anti-tumor effects of Marsdenia Tenacissima Extract (MTE).
    Li Z, Hao H, Tian W, Jiao Y, Deng X, Han S, Han J.
    J Ethnopharmacol; 2020 Mar 25; 250():112524. PubMed ID: 31884032
    [Abstract] [Full Text] [Related]

  • 7. Marsdenia tenacissima extract overcomes Axl- and Met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells.
    Han SY, Zhao W, Han HB, Sun H, Xue D, Jiao YN, He XR, Jiang ST, Li PP.
    Oncotarget; 2017 Aug 22; 8(34):56893-56905. PubMed ID: 28915640
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF.
    Fu JL, Hao HF, Wang S, Jiao YN, Li PP, Han SY.
    J Ethnopharmacol; 2022 Nov 15; 298():115607. PubMed ID: 35973634
    [Abstract] [Full Text] [Related]

  • 10. Marsdenia tenacissima extract induces endoplasmic reticulum stress-associated immunogenic cell death in non-small cell lung cancer cells through targeting AXL.
    Yuan Y, Guo Y, Guo ZW, Hao HF, Jiao YN, Deng XX, Han SY.
    J Ethnopharmacol; 2023 Oct 05; 314():116620. PubMed ID: 37207882
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.
    J Exp Clin Cancer Res; 2014 Jun 17; 33(1):52. PubMed ID: 24939055
    [Abstract] [Full Text] [Related]

  • 12. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.
    Anticancer Drugs; 2013 Nov 17; 24(10):1039-46. PubMed ID: 23962905
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor activity and relative mechanism of ethanolic extract of Marsdenia tenacissima (Asclepiadaceae) against human hematologic neoplasm in vitro and in vivo.
    Ye B, Li J, Li Z, Yang J, Niu T, Wang S.
    J Ethnopharmacol; 2014 Apr 11; 153(1):258-67. PubMed ID: 24583069
    [Abstract] [Full Text] [Related]

  • 14. Marsdenia tenacissima extract induces G0/G1 cell cycle arrest in human esophageal carcinoma cells by inhibiting mitogen-activated protein kinase (MAPK) signaling pathway.
    Fan W, Sun L, Zhou JQ, Zhang C, Qin S, Tang Y, Liu Y, Lin SS, Yuan ST.
    Chin J Nat Med; 2015 Jun 11; 13(6):428-37. PubMed ID: 26073339
    [Abstract] [Full Text] [Related]

  • 15. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 16. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 01; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 17. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 01; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 19. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 20. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
    Lin YC, Lin YC, Shih JY, Huang WJ, Chao SW, Chang YL, Chen CC.
    Clin Cancer Res; 2015 Jan 15; 21(2):428-38. PubMed ID: 25593344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.